Sahajanand Medical Technologies is preparing for its IPO from October 15 to October 19, 2026, alongside a pre-IPO funding round. Valued at ₹3,500 crore, the medical device maker reported strong growth, yet investors should note the issue is an offer-for-sale, meaning the company will not receive capital for itself. Key risks include heavy reliance on a single product line and significant debt levels.
Sahajanand Medical Technologies is set to enter the public market this week, with its initial public offering (IPO) scheduled to open for subscription from October 15 to October 19, 2026. Ahead of this listing, the company is also conducting a pre-IPO funding round, aiming to raise between ₹175 crore and ₹200 crore. The firm has set a price band of ₹327 to ₹344 per share, targeting a market valuation of approximately ₹3,500 crore. Shares are expected to list on the stock exchanges on October 23, 2026.
The company has demonstrated strong financial growth leading up to this event. For the fiscal year ending in 2026, Sahajanand Medical Technologies reported revenue of ₹1,210.5 crore, a notable increase from ₹1,024.9 crore in the previous year. Net profit also improved significantly, reaching ₹69.08 crore compared to ₹25.15 crore in the prior fiscal year. The company holds a significant position in the Indian market, particularly with about a 25% market share in the drug-eluting stent segment, which are medical devices used to open narrowed or blocked arteries.
Investors evaluating the IPO should pay close attention to the structure of the issue. The entire offering is an offer-for-sale, meaning existing investors are selling their shares to the public. As a result, the company will not receive any of the money raised in this IPO to fund its own business growth or expansion plans. The primary goal of the issue is to provide an exit route for current shareholders, including private equity investors who have backed the firm for several years.
While the company has shown revenue growth, it faces specific operational risks that investors should monitor. A major point of concern is the company's heavy reliance on its flagship product, 'Supraflex Cruz.' Because a significant portion of the firm's revenue comes from this single product line, any regulatory issues, competitive pricing, or changes in medical preferences regarding this specific device could impact its financial performance. Additionally, the company depends on imported raw materials for manufacturing, which can make it vulnerable to global supply chain disruptions and currency fluctuations.
Another important factor is the company’s financial health regarding its use of borrowed money. As of June 2026, the company reported total debt of approximately ₹320.63 crore. High debt levels require the company to generate steady cash flow to manage interest payments and repayments, which is essential to track alongside its profit margins. Investors looking at the upcoming listing may want to watch for subscription trends during the bidding period and the final allocation results, which will reflect market sentiment toward the medical device sector and the company’s long-term business model.